6398-50-1

Usage

Uses

Used in Pharmaceutical Production:
1-Cyano-6-methoxy-3,4-dihydronaphtalene is used as a precursor in the synthesis of various pharmaceutical compounds, leveraging its reactivity and chemical structure to facilitate the creation of new medications.
Used in Organic Synthesis:
In the field of organic synthesis, 1-Cyano-6-methoxy-3,4-dihydronaphtalene serves as a key intermediate, enabling the development of complex organic molecules for a range of applications.
Used in Medicinal Chemistry Research:
As a research tool, 1-Cyano-6-methoxy-3,4-dihydronaphtalene is utilized in the study of organic chemistry and drug development, providing insights into the properties and potential applications of related compounds in the field of medicinal chemistry.

InChI:InChI=1/C12H11NO/c1-14-11-5-6-12-9(7-11)3-2-4-10(12)8-13/h4-7H,2-3H2,1H3

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 1730-48-9 6-methoxy-1,2,3,4-tetrahydronaphthalene 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 
• 22557-02-4 1-Cyano-1-hydroxy-6-methoxytetralon 
• 80859-07-0 6-methoxy-1-(trimethylsilanyloxy)-1,2,3,4-tetrahydronaphthalene-1-carbonitrile 
• 5804-85-3 diethylaluminium cyanide 

Downstream Products

• 77029-01-7 6-methoxy-[1]naphthonitrile 
• 2472-22-2 6-methoxy-2-tetralone 
• 77029-02-8 2-(6-methoxy-1-naphthyl)-1-phenyl-2-propanol 
• 58149-89-6 1-(6-methoxynaphthalen-1-yl)ethanone 
• 130200-57-6 6-hydroxynaphthalene-1-carbonitrile 

Relevant academic research and scientific papers

Enantioselective catalytic fluorinative aza-semipinacol rearrangement

An efficient and highly stereoselective fluorinative aza-semipinacol rearrangement is described. The catalytic reaction requires use of Selectfluor in combination with the chiral, enantiopure phosphate anion derived from acid L3. Under optimized condition

Enantioselective synthesis of (-)-methoxyestrone

Enantioselective synthesis of unnatural (-)-methoxyestrone in 12 steps from the commercially available tetralone based on the formation of a chiral bicyclic intermediate having the A-B steroid ring framework was accomplished. The crucial synthetic step co

Suzuki-Miyaura cross-coupling reaction of naphthyl triflate with indole boronic acids catalyzed by a recyclable polymer-supported N-heterocyclic carbene-palladium complex catalyst: Synthesis of naphthalene-linked bis-heterocycles

In this study, the Suzuki-Miyaura cross-coupling reaction of naphthyl triflate with indole boronic acids catalyzed by a recyclable polymer-supported Pd-NHC complex catalyst is presented. The polymer-supported catalyst can be reused several times retaining high activity for the transformation. The structures of all the synthesized compounds were established by elemental analysis and from their mass, 1H-NMR, and 13C-NMR spectra.

Structure-activity studies for a novel series of N-(arylethyl)-N- (1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines possessing dual 5- HT uptake inhibiting and α2-antagonistic activities

In search of an α2-antagonist/5-HT uptake inhibitor as a potential new class of antidepressant with a more rapid onset of action, compound 3 was prepared and observed to possess high affinity for the α2-receptor (K(i) = 6.71 nM) and

Synthesis of 2-tetralones via a novel 1,2-carbonyl transposition of 1-tetralones

Simple acidic hydrolysis of epoxyamides 4, derived from 1-tetralones, furnishes the corresponding 2-tetralones in good yield.

Photoexcited proton transfer from enhanced photoacids

Naphthols with electron-withdrawing groups such as cyano or methanesulfonyl at C-5 and C-8 exhibit greatly enhanced photoacidity. This increase in photoacidity enables the substituted naphthols to undergo excited-state proton transfer (ESPT) in alcohols and Me2SO in the absence of water. In aqueous tetrahydrofuran solution, efficient proton transfer to water occurs at much lower water concentrations than with the parent naphthol, and the kinetics of proton transfer indicate that a smaller water cluster is involved.

Biogentic amine uptake inhibitors

Compounds of the formula: STR1 or a pharmaceutically acceptable salt thereof, wherein m is 0, 1 or 2 and n is 0 or 1; R1 is hydrogen or lower alkyl; R2 is C1 -C6 -alkyl substituted with a heterocyclic group or C7 -C16 -arylalkyl, wherein the aryl group is unsubstituted or substituted with from one to three non-hydrogen members independently selected from the group consisting of halogen, C1 -C6 -alkyl, halo-C1 -C6 -alkyl, C1 -C6 -alkoxy, hydroxy, amino and C1 -C6 -alkylamino; R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen, C1 -C6 -alkoxy, C1 -C6 -alkyl, halogen, and halo-C1 -C6 -alkyl, or any two of R3, R4, R5 and R6 taken together form a methylenedioxy group; and R7 is hydrogen or C1 -C6 -alkyl. These compounds are useful as inhibitors of the neuronal uptake of biogenic amines and for the treatment of affective disorders, such as, for example, depression.

1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES

Compounds of the formula STR1 and pharmaceutically acceptable salt thereof, wherein R 2 is selected from hydroxy and lower alkoxy, R 5 is lower alkyl, and R 11 and R 12 are independently selected from hydrogen, halo, hydroxy, methoxy, and lower alkyl, are selective . alpha.. sub.2 adrenergic receptor antagonists useful in the treatment of glaucoma.

1-aminomethyl-1,2,3,4-tetrahydronaphthalenes

The present invention provides compounds of the formula STR1 or a pharmaceutically acceptable salt thereof wherein R1 is selected from hydrogen, halo, lower alkyl, lower alkoxy, or thioalkoxy; and R2 is lower alkoxy; or R1 and R2 together form a methylenedioxy or ethylenedioxy ring; R3 and R4 are independently selected from hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, (lower alkyl)amino, (lower alkylsulfonyl)amino, and halo; and R7 is selected from the group consisting of 2- or 3-thienyl, 2- or 3-furyl, and STR2 where R13 and R14 are independently selected from the group consisting of hydrogen, hydroxy, halogen, amino, lower alkyl, lower alkoxy, lower alkylthio, methylenedioxy, or ethylenedioxy. The compounds of the present invention selectively inhibit α2 -adrenergic receptors as well as inhibit the uptake of biogenic amines and are thus useful in the treatment of certain cardiovascular and psychiatric disorders.